301 related articles for article (PubMed ID: 37459879)
1. Effectiveness of previous infection-induced and vaccine-induced protection against hospitalisation due to omicron BA subvariants in older adults: a test-negative, case-control study in Quebec, Canada.
Carazo S; Skowronski DM; Brisson M; Sauvageau C; Brousseau N; Fafard J; Gilca R; Talbot D; Ouakki M; Febriani Y; Deceuninck G; De Wals P; De Serres G
Lancet Healthy Longev; 2023 Aug; 4(8):e409-e420. PubMed ID: 37459879
[TBL] [Abstract][Full Text] [Related]
2. Protection against omicron (B.1.1.529) BA.2 reinfection conferred by primary omicron BA.1 or pre-omicron SARS-CoV-2 infection among health-care workers with and without mRNA vaccination: a test-negative case-control study.
Carazo S; Skowronski DM; Brisson M; Barkati S; Sauvageau C; Brousseau N; Gilca R; Fafard J; Talbot D; Ouakki M; Gilca V; Carignan A; Deceuninck G; De Wals P; De Serres G
Lancet Infect Dis; 2023 Jan; 23(1):45-55. PubMed ID: 36152671
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and durability of BNT162b2 vaccine against hospital and emergency department admissions due to SARS-CoV-2 omicron sub-lineages BA.1 and BA.2 in a large health system in the USA: a test-negative, case-control study.
Tartof SY; Slezak JM; Puzniak L; Hong V; Frankland TB; Xie F; Ackerson BK; Valluri SR; Jodar L; McLaughlin JM
Lancet Respir Med; 2023 Feb; 11(2):176-187. PubMed ID: 36216013
[TBL] [Abstract][Full Text] [Related]
4. Risk of reinfection, vaccine protection, and severity of infection with the BA.5 omicron subvariant: a nation-wide population-based study in Denmark.
Hansen CH; Friis NU; Bager P; Stegger M; Fonager J; Fomsgaard A; Gram MA; Christiansen LE; Ethelberg S; Legarth R; Krause TG; Ullum H; Valentiner-Branth P
Lancet Infect Dis; 2023 Feb; 23(2):167-176. PubMed ID: 36270311
[TBL] [Abstract][Full Text] [Related]
5. SARS-CoV-2 infection following booster vaccination: Illness and symptom profile in a prospective, observational community-based case-control study.
Antonelli M; Penfold RS; Canas LDS; Sudre C; Rjoob K; Murray B; Molteni E; Kerfoot E; Cheetham N; Pujol JC; Polidori L; May A; Wolf J; Modat M; Spector T; Hammers A; Ourselin S; Steves C
J Infect; 2023 Dec; 87(6):506-515. PubMed ID: 37777159
[TBL] [Abstract][Full Text] [Related]
6. BNT162b2 vaccine protection against omicron and effect of previous infection variant and vaccination sequence among children and adolescents in Singapore: a population-based cohort study.
Yung CF; Pang D; Kam KQ; Lye DC; Ong B; Chong CY; Tan KB
Lancet Child Adolesc Health; 2023 Jul; 7(7):463-470. PubMed ID: 37201540
[TBL] [Abstract][Full Text] [Related]
7. Estimated Protection of Prior SARS-CoV-2 Infection Against Reinfection With the Omicron Variant Among Messenger RNA-Vaccinated and Nonvaccinated Individuals in Quebec, Canada.
Carazo S; Skowronski DM; Brisson M; Sauvageau C; Brousseau N; Gilca R; Ouakki M; Barkati S; Fafard J; Talbot D; Gilca V; Deceuninck G; Garenc C; Carignan A; De Wals P; De Serres G
JAMA Netw Open; 2022 Oct; 5(10):e2236670. PubMed ID: 36239934
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study.
Tsang NNY; So HC; Cowling BJ; Leung GM; Ip DKM
Lancet Infect Dis; 2023 Apr; 23(4):421-434. PubMed ID: 36521506
[TBL] [Abstract][Full Text] [Related]
9. Duration of protection of ancestral-strain monovalent vaccines and effectiveness of bivalent BA.1 boosters against COVID-19 hospitalisation in England: a test-negative case-control study.
Kirsebom FCM; Andrews N; Stowe J; Ramsay M; Lopez Bernal J
Lancet Infect Dis; 2023 Nov; 23(11):1235-1243. PubMed ID: 37453440
[TBL] [Abstract][Full Text] [Related]
10. Protection against symptomatic infection with delta (B.1.617.2) and omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants after previous infection and vaccination in adolescents in England, August, 2021-March, 2022: a national, observational, test-negative, case-control study.
Powell AA; Kirsebom F; Stowe J; Ramsay ME; Lopez-Bernal J; Andrews N; Ladhani SN
Lancet Infect Dis; 2023 Apr; 23(4):435-444. PubMed ID: 36436536
[TBL] [Abstract][Full Text] [Related]
11. Vaccine effectiveness and duration of protection of COVID-19 mRNA vaccines against Delta and Omicron BA.1 symptomatic and severe COVID-19 outcomes in adults aged 50 years and over in France.
Tamandjou Tchuem CR; Auvigne V; Vaux S; Montagnat C; Paireau J; Monnier Besnard S; Gabet A; Benhajkassen N; Le Strat Y; Parent Du Chatelet I; Levy-Bruhl D
Vaccine; 2023 Mar; 41(13):2280-2288. PubMed ID: 36870880
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of the booster dose of inactivated COVID-19 vaccine against Omicron BA.5 infection: a matched cohort study of adult close contacts.
Zeng T; Lu Y; Zhao Y; Guo Z; Sun S; Teng Z; Tian M; Wang J; Li S; Fan X; Wang W; Cai Y; Liao G; Liang X; He D; Wang K; Zhao S
Respir Res; 2023 Oct; 24(1):246. PubMed ID: 37828565
[TBL] [Abstract][Full Text] [Related]
13. Neutralization of Omicron subvariants BA.1 and BA.5 by a booster dose of COVID-19 mRNA vaccine in a Japanese nursing home cohort.
Itamochi M; Yazawa S; Inasaki N; Saga Y; Yamazaki E; Shimada T; Tamura K; Maenishi E; Isobe J; Nakamura M; Takaoka M; Sasajima H; Kawashiri C; Tani H; Oishi K
Vaccine; 2023 Mar; 41(13):2234-2242. PubMed ID: 36858871
[TBL] [Abstract][Full Text] [Related]
14. Estimated BNT162b2 Vaccine Effectiveness Against Infection With Delta and Omicron Variants Among US Children 5 to 11 Years of Age.
Khan FL; Nguyen JL; Singh TG; Puzniak LA; Wiemken TL; Schrecker JP; Taitel MS; Zamparo JM; Jodar L; McLaughlin JM
JAMA Netw Open; 2022 Dec; 5(12):e2246915. PubMed ID: 36515946
[TBL] [Abstract][Full Text] [Related]
15. Estimation of COVID-19 mRNA Vaccine Effectiveness and COVID-19 Illness and Severity by Vaccination Status During Omicron BA.4 and BA.5 Sublineage Periods.
Link-Gelles R; Levy ME; Natarajan K; Reese SE; Naleway AL; Grannis SJ; Klein NP; DeSilva MB; Ong TC; Gaglani M; Hartmann E; Dickerson M; Stenehjem E; Kharbanda AB; Han J; Spark TL; Irving SA; Dixon BE; Zerbo O; McEvoy CE; Rao S; Raiyani C; Sloan-Aagard C; Patel P; Dascomb K; Uhlemann AC; Dunne MM; Fadel WF; Lewis N; Barron MA; Murthy K; Nanez J; Griggs EP; Grisel N; Annavajhala MK; Akinseye A; Valvi NR; Goddard K; Mamawala M; Arndorfer J; Yang DH; Embí PJ; Fireman B; Ball SW; Tenforde MW
JAMA Netw Open; 2023 Mar; 6(3):e232598. PubMed ID: 36920396
[TBL] [Abstract][Full Text] [Related]
16. Vaccine effectiveness of two-dose BNT162b2 against symptomatic and severe COVID-19 among adolescents in Brazil and Scotland over time: a test-negative case-control study.
Florentino PTV; Millington T; Cerqueira-Silva T; Robertson C; de Araújo Oliveira V; Júnior JBS; Alves FJO; Penna GO; Vital Katikireddi S; Boaventura VS; Werneck GL; Pearce N; McCowan C; Sullivan C; Agrawal U; Grange Z; Ritchie LD; Simpson CR; Sheikh A; Barreto ML; Rudan I; Barral-Netto M; Paixão ES
Lancet Infect Dis; 2022 Nov; 22(11):1577-1586. PubMed ID: 35952702
[TBL] [Abstract][Full Text] [Related]
17. Protection Conferred by COVID-19 Vaccination, Prior SARS-CoV-2 Infection, or Hybrid Immunity Against Omicron-Associated Severe Outcomes Among Community-Dwelling Adults.
Lee N; Nguyen L; Austin PC; Brown KA; Grewal R; Buchan SA; Nasreen S; Gubbay J; Schwartz KL; Tadrous M; Wilson K; Wilson SE; Kwong JC
Clin Infect Dis; 2024 May; 78(5):1372-1382. PubMed ID: 38001037
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of primary series and booster vaccination against SARS-CoV-2 infection and hospitalisation among adolescents aged 12-17 years in Singapore: a national cohort study.
Chiew CJ; Premikha M; Chong CY; Wei WE; Ong B; Lye DC; Heng D; Lee VJ; Tan KB
Lancet Infect Dis; 2023 Feb; 23(2):177-182. PubMed ID: 36182678
[TBL] [Abstract][Full Text] [Related]
19. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study.
Nyberg T; Ferguson NM; Nash SG; Webster HH; Flaxman S; Andrews N; Hinsley W; Bernal JL; Kall M; Bhatt S; Blomquist P; Zaidi A; Volz E; Aziz NA; Harman K; Funk S; Abbott S; ; Hope R; Charlett A; Chand M; Ghani AC; Seaman SR; Dabrera G; De Angelis D; Presanis AM; Thelwall S
Lancet; 2022 Apr; 399(10332):1303-1312. PubMed ID: 35305296
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of BNT162b2 Vaccine Against Omicron-SARS-CoV-2 Subvariants in Children 5-11 Years of Age in Quebec, Canada, January 2022 to January 2023.
Razafimandimby H; Sauvageau C; Ouakki M; Carazo S; Skowronski DM; De Serres G
Pediatr Infect Dis J; 2024 Jan; 43(1):32-39. PubMed ID: 37922479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
